Yale Tobacco Center of Regulatory Sciences Suchitra Krishnan-Sarin, Ph.D.. Stephanie O’Malley, Ph.D..

Slides:



Advertisements
Similar presentations
UNIVERSITY OF MARYLAND SCHOOL OF LAW The Basis of a Comprehensive Regulatory Policy for Reduced Harm Tobacco Products David Sweanor, Adjunct Professor.
Advertisements

09-Sep-2003 Predicting human risk with animal research: lessons learned from caffeine/ephedrine combinations Richard J. Briscoe, Ph.D. Safety Pharmacology.
Nicotine and Caffeine Chapter 12. Leaves of the Nicotiana tabacum plant Nicotine History.
Why Bother? It’s in Your Head Slay the Dragon Talk.
Alcohol and Nicotine Dependence: Shared Mechanisms Stephanie O’Malley, Ph.D. Yale University School of Medicine.
Teen Smoking Prevention
Substance abuse refers to the continued use of the substance despite knowing problems associated with the substance such as persistent desire to use it.
* Imagine that everyone in this room is a smoker. * Half go to one side * Half go to the other * What do you think this represents?
Opiate and Nicotine Addiction: Involvement of cAMP Response Element Binding Protein (CREB) Matt Wolfe
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
Tobacco Chapter 8 ???? ____ % of new smokers are adolescents/teenagers ???? Smokers have about a _____% greater risk of dying from coronary heart disease.
What Do Toxicologists Do?
Examination of Age-Related Cholinergic Activity during Nicotine Exposure and Withdrawal Luis M Carcoba, M.D, Ph.D. University of Texas at El Paso Department.
Psychiatric Comorbidity of Smoking and Nicotine Dependence: An Epidemiologic Perspective Naomi Breslau, Ph.D. Department of Epidemiology Michigan State.
Bringing the Full Power of Science to Bear on Bringing the Full Power of Science to Bear on NIDA NATIONAL INSTITUTE ON DRUG ABUSE Drug Abuse & Addiction.
Genetics & Addiction Jonathan D. Pollock, Ph.D. Division of Neuroscience & Behavioral Research National Institute on Drug Abuse National Institutes of.
 Most drug use starts and peaks during adolescence  76.5% of all teens (
Alcohol & other addictions: can DNA make a difference? Dr Martin Kennedy Department of Pathology Christchurch School of Medicine & Health Sciences University.
Role of Medications in Recovery and the Prevention of Relapse Mark Publicker, MD FASAM Medical Director, Mercy Recovery Center, Westbrook Maine.
This is your Brain: Teaching About Neuroscience and Addiction Research
Presented By: Tonya Lee, Crystal Culpepper, Lauren Raulerson, and Nathan Brantley.
4th Annual Thoughtful Pain Management
1 Questions to the Subcommittee 1.What criteria do you recommend to TPSAC for selecting the initial list of H/PH constituents?
Alcohol Abuse and Alcoholism
An Educational Perspective Based on Information Contained In The Indiana Prevention Resource Center Factline on Tobacco.
Chapter 18 Psychoactive Substance Use Disorders: Drugs.
20th Century World War 1 (soldier’s relief) 1920’s beginning of heavy marketing World War II Marlboro Man 1964 Smoking linked to cancer 1971 advertisements.
CDC’s Best Practices for Comprehensive Tobacco Control Programs Jerelyn Jordan Centers for Disease Control and Prevention Office on Smoking and Health.
 2007 Johns Hopkins Bloomberg School of Public Health Tobacco Control Surveillance Benjamin Apelberg, PhD, MHS Institute for Global Tobacco Control Johns.
The Effect of Product Characteristics on Perceptions of E-cigarettes among Canadians Christine Czoli, PhD Student May 28, 2014.
Nicotine Dependence Laurie Zawertailo, PhD Adjunct Research Scientist Clinical Neuroscience, CAMH.
 2011 Johns Hopkins Bloomberg School of Public Health Jonathan M. Samet, MD, MS Director, USC Institute for Global Health Professor and Flora L. Thornton.
Multiple Neuronal Systems Thought to be Involved in Nicotine Dependence Frank Vocci, Ph.D. Director Division of Treatment Research and Development National.
Drugs. What is a Psychoactive Drug? Chemical substance that alters perceptions, mood, or behavior through their actions at the neural synapse Chemical.
 Addiction Objective 3.1 and 3.2.  Take the addiction quiz Objective 3.1 and 3.2.
CCTN September 6 th, Recent Scientific Publications from the Clinical Trials Network David Liu, M.D. (CTN-0029) Harold Perl, Ph.D. (CTN-0015) Paul.
GENES and TOBACCO USE. CAN GENES PREDICT WHO WILL… develop heart disease? develop lung cancer? become a smoker? be able to quit?
Basic Behavioral Neurobiology of Drug Addiction J. David Jentsch, Ph.D. Assistant Professor of Psychology (Behavioral Neuroscience)
Prepared by: Dr. Mohammad Shaikhani University of Sulaimani College of Medicine. Dept of Medicine.
Bledsoe et al., Paramedic Care Principles & Practice Volume 1: Introduction © 2006 by Pearson Education, Inc. Upper Saddle River, NJ Basic Pharmacology.
DRUG ABUSE BY KEITH ARLINE HIGH SCHOOL STUDENTS. It’s a disease of the brain Causes compulsive drug seeking Disrupts ability to resist impulses Damage.
Nicotine and Caffeine Chapter 12. Leaves of the Nicotiana tabacum plant Nicotine History.
REPORT From the Basic Science Review Work Group National Institute on Drug Abuse May 2006 National Institute on Drug Abuse Division of Basic Neuroscience.
Tobacco Use Reduction as a National and Regional Priority Tobacco-free College Campuses: Promoting a Culture of Health Patrick O’Carroll, MD, MPH Assistant.
The FDA: Basic Facts It takes 12 to 15 years to develop a single drug Only 1 in 10,000 potential medications makes it completely through the process Only.
Animal Models of Ethanol and Nicotine Interactions.
PCPA Outpatient Summit Joan Erney, J.D. Office of Mental Health & Substance Abuse Services December 2, 2009.
 Tobacco is a product prepared from the leaves of the tobacco plant.  It is smoked in cigarettes, cigars, pipes and consumed as snuff, chewing tobacco.
Associations between Beliefs about E-cigarettes and Public Support for Regulating E-cigarettes Chul-joo Lee, Andy Tan, Cabral Bigman, & Kyungbo Kim.
NICOTINE and the BRAIN Wilson M. Compton, MD, MPE Deputy Director, U.S. National Institute on Drug Abuse.
Risk factors in the Development of addiction. Why are some people more venerable to addiction than others?
Drug Regulation, Development, Names, and Information Chapter 3 Copyright (c) 2004 Elsevier Inc. All rights reserved.
David Perry Professor Dept. of Pharmacology & Physiology
11/6/03LSRO presentation Draft for discussion PM USA Mission Our goal is to be the most responsible, effective and respected developer, manufacturer and.
Varenicline: A Tale of Three Molecules Douglas E. Jorenby, Ph.D. Associate Professor of Medicine Univ. of WI School of Medicine and Public Health The Center.
NICOTINE and the BRAIN Wilson M. Compton, MD, MPE Deputy Director, U.S. National Institute on Drug Abuse.
The Science of Addiction. Homelessness Crime Violence Homelessness Crime Violence Neurotoxicity AIDS, Cancer Mental illness Neurotoxicity AIDS, Cancer.
The Dangers of Nicotine: Pathway to Addiction? Module 9 Assignment ADC 655 Wade A. Wilkins Aspen University December 21, 2015.
The process of drug development. Drug development 0,8 – 1 mld. USD.
Meet & Greet. Welcome Objectives: 1. Review the core terminology used in pharmacology. 2. Discuss the features of the “perfect” drug. 3. Examine the.
Ecstasy/Molly/MDMA. What is MDMA? An psychoactive, synthetic drug Has similarities to both the stimulant amphetamine and the hallucinogen mescaline. Initially.
Development and Implementation of a Tobacco Cessation Toolkit
DISCOVERING PSYCHOLOGY
Price of Drug Addiction
Adolescents and Substance Abuse
Motivation Not all responses can be explained by
Drug Abuse Munir Gharaibeh, MD, PhD, MHPE
CanMEDS Roles Covered Medical Expert (as Medical Experts, physicians integrate all of the CanMEDS Roles, applying medical knowledge, clinical skills, and.
CanMEDS Roles Covered Medical Expert (as Medical Experts, physicians integrate all of the CanMEDS Roles, applying medical knowledge, clinical skills, and.
Tobacco.
Presentation transcript:

Yale Tobacco Center of Regulatory Sciences Suchitra Krishnan-Sarin, Ph.D.. Stephanie O’Malley, Ph.D..

Goals Overarching: Reduce Addiction to Tobacco Products Specific: Evaluation of the Influence of Flavors (like Menthol), Sweeteners, and Other Attributes on the Addictive Potential of Tobacco Products

Why Flavors and Sweeteners? Flavors banned in cigarettes. Menthol still present in most cigarettes, even in those not sold as menthol cigarettes. Flavors are present in most other tobacco products, especially newer products like e-cigarettes. Sweeteners are present in tobacco products.

Flavors are everywhere!

For successful regulation of flavors and sweeteners empirical evidence on what they do is essential Yale TCORS will examine if flavors alter reinforcement from tobacco products If so – how do they alter reinforcement? – Is this effect dose dependent?

Approach Translational Multiple methods and disciplines Four proposed studies that bridge basic, clinical and population science – Results will be integrated to develop a more comprehensive understanding of the role of flavors and sweeteners

Core Team Includes Experts in… Chemosensory perceptions (Barry Green) Menthol and irritant receptor biology (Sven Jordt) Dopamine and brain reward pathways (Nii Addy) Nicotinic receptor biology (Marina Picciotto) Adolescent tobacco use (Suchitra Krishnan-Sarin) Human behavioral pharmacology (Mehmet Sofuoglu) Tobacco addiction (Stephanie O’Malley/Benjamin Toll) Clinical pharmacokinetics of drugs of abuse (Peter Jatlow) Health economics and decision making science (Jody Sindelar/ Johanna Catherine Maclean)

Yale TCORS organization

Project 1 Project 1: Effect of Flavors on Nicotine Choice and Central Reward mechanisms In new consumers of dissolvable tobacco products, do menthol and other flavors counteract the initial aversive effects of nicotine and tobacco aromas? In chronic consumers, do sweeteners and menthol increase the addictive properties of tobacco products ? – If so, is this mediated through enhancing central dopaminergic mechanisms Sven Jordt, Ph.D.Marina Picciotto, Ph.D.Nii Addy, Ph.D.

Project 1: Project 1: Effect of Flavors on Nicotine Choice and Central Reward mechanisms Determine whether flavor constituents in dissolvable tobacco products alter nicotine intake and nicotine reinforcement using – Oral nicotine choice paradigms with adolescent and adult mice, and mice deficient in receptors for menthol and sweeteners (TRPM8, TRPA1, T1R2/3) – Fast scan cyclic voltammetry to measure dopamine release during nicotine and menthol/ sweetener self-administration in rats

Project 2: Project 2: Menthol’s Effects on Nicotine Reinforcement in Smokers In young adults, does acute menthol administration via either e-cigarettes or sublingual tablets enhance the reinforcing effects of intravenously administered pure nicotine? Mehmet Sofuoglu,M.D.,Ph.D.Barry Green, Ph.D. Gerald Valentine,M.D.

Project 2: Project 2: Menthol’s Effects on Nicotine Reinforcement in Smokers Two pilot studies to determine menthol doses – E-cigarettes and dissolvables Two double-blind, placebo-controlled studies with – E-cigarettes and dissolvables Each study – Crossover design – Reinforcement from IV nicotine doses will be examined High or low dose of menthol or a control flavor

Project 3: Project 3: Flavor and E-cigarette Effects in Adolescent Smokers In adolescent smokers – does presence of menthol and/or other flavors in e-cigarettes influence reinforcement? – Does preference for menthol predict the type of tobacco product used at one year follow up ? Suchitra Krishnan-Sarin, Ph.DBarry Green, Ph.D.

Project 3 Project 3: Flavor and E-cigarette Effects in Adolescent Smokers Two pilots – Psychophysical chemosensory studies to determine high and low doses of menthol and other flavors for e-cigarettes Two double-blind, placebo-controlled studies – Crossover design – Reinforcement from one of three different doses of nicotine  High or low dose of menthol or a control flavor

Project 4: Project 4: Economics, Experiments and PATH: Creating Knowledge for Tobacco Regulation To examine how individuals perceive and trade-off the risks of different attributes of cigarettes – levels of nicotine – levels of toxins – flavorings To examine the impact of flavorings and other attributes on perceptions of risk about cigarettes and e-cigarettes Jody Sindelar, Ph.DJohanna Catherine Maclean, Ph.D

Project 4: Project 4: Economics, Experiments and PATH: Creating Knowledge for Tobacco Regulation To study how sources of information affect the credibility of information about menthol in cigarettes and e-cigarettes. To examine peer effects on use of e-cigarettes. Use secondary data combined with findings from our experiments to predict the national use of MRTPs and to estimate the impact of potential FDA regulations.

Cores Administrative Career Development Pilot Core Laboratory Core Marina Picciotto, Ph.DMarney White, Ph.D Benjamin Toll, Ph.DStephanie O’Malley Ph.D Peter Jatlow, M.D.Tore Eid, M.D., Ph.D Stephanie O’Malley, Ph.DSuchitra Krishnan-Sarin, Ph.D

Center Specific Resources Analytics – Nicotine metabolites, menthol Molecular neuroscience Animal behavior – IV Nicotine self-administration, operant paradigms Human laboratory paradigms – IV nicotine administration and self-administration, tobacco product self- administration, smoking topography – Human sensory measurements Health economics/Discrete choice experiments

Expertise and access to populations Substance abusers Psychiatric co-morbidities Medically ill patients, including cancer patients Adolescents and young adults Women’s health Veterans

Other Resources Proteomics and Genomics Neuroimaging: PET, SPECT, fmRI, MRS Data Collection Platforms: Teleforms, Qualtrics, Oncore, Sample Repository Ethics of research in vulnerable populations